Joachim Riethmueller
Overview
Explore the profile of Joachim Riethmueller including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
139
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schaefer J, Hector A, Schmidt K, Teufel M, Fleischer S, Graepler-Mainka U, et al.
Eur Radiol
. 2017 Jul;
28(1):74-84.
PMID: 28664245
Objectives: To evaluate the applicability of a semiquantitative MRI scoring system (MR-CF-S) as a prognostic marker for clinical course of cystic fibrosis (CF) lung disease. Methods: This observational study of...
2.
Adams C, Icheva V, Deppisch C, Lauer J, Herrmann G, Graepler-Mainka U, et al.
Cell Physiol Biochem
. 2016 Jul;
39(2):565-72.
PMID: 27395380
Background/aims: Several recent clinical studies revealed an accumulation of ceramide in bronchial epithelial cells of patients with cystic fibrosis (CF). Degradation of ceramide concentrations in lungs of CF patients employing...
3.
Hector A, Kirn T, Ralhan A, Graepler-Mainka U, Berenbrinker S, Riethmueller J, et al.
J Cyst Fibros
. 2016 Feb;
15(3):340-9.
PMID: 26856310
With intensified antibiotic therapy and longer survival, patients with cystic fibrosis (CF) are colonized with a more complex pattern of bacteria and fungi. However, the clinical relevance of these emerging...
4.
Hector A, Schafer H, Poschel S, Fischer A, Fritzsching B, Ralhan A, et al.
Am J Respir Crit Care Med
. 2015 Jan;
191(8):914-23.
PMID: 25632992
Rationale: Patients with cystic fibrosis (CF) lung disease have chronic airway inflammation driven by disrupted balance of T-cell (Th17 and Th2) responses. Regulatory T cells (Tregs) dampen T-cell activation, but...
5.
Hector A, Kormann M, Kammermeier J, Burdi S, Marcos V, Rieber N, et al.
Am J Respir Cell Mol Biol
. 2012 Oct;
48(1):71-7.
PMID: 23043087
A genome-wide association study identified interferon-related development regulator-1 (IFRD1), a protein expressed by neutrophils, as a key modifier gene in cystic fibrosis (CF) lung disease. Here, we investigated the expression...
6.
Wiegand G, Binder W, Ulmer H, Kaulitz R, Riethmueller J, Hofbeck M
Pediatr Cardiol
. 2012 Feb;
33(7):1109-14.
PMID: 22354224
In the majority of patients, secundum atrial septal defects (ASDs) are treated interventionally or surgically, before the onset of clinical symptoms, between 3 and 6 years of age. Because right-ventricular...
7.
Riethmueller J, Kumpf M, Borth-Bruhns T, Brehm W, Wiskirchen J, Sieverding L, et al.
Cell Physiol Biochem
. 2009 Mar;
23(1-3):205-10.
PMID: 19255515
Introduction: At present no evidence-based medical treatment for persistent atelectasis in pediatric non-cystic fibrosis (CF) patients is available. Method: To evaluate the use of intratracheally instilled recombinant human deoxyribonuclease (rhDNase)...
8.
Riethmueller J, Vonthein R, Borth-Bruhns T, Grassme H, Eyrich M, Schilbach K, et al.
Cell Physiol Biochem
. 2008 Sep;
22(1-4):347-52.
PMID: 18769062
Background: Inhaled rhDNase may improve sputum viscosity and mucociliary clearance by cleavage of extracellular DNA derived for instance from dead leukocytes in purulent, highly viscous patient sputum. Methods: Here we...
9.
Riethmueller J, Borth-Bruhns T, Kumpf M, Vonthein R, Wiskirchen J, Stern M, et al.
Pediatr Pulmonol
. 2005 Nov;
41(1):61-6.
PMID: 16265663
Recombinant human deoxyribonuclease I (dornase alfa) is currently used as an inhaled mucoactive agent in the treatment of cystic fibrosis. In a randomized, placebo-controlled, double-blind clinical study in 100 infants,...